Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERASNASDAQ:MREONASDAQ:OPNTNASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.48-3.3%$1.34$1.01▼$3.45$419.27M1.091.75 million shs1.46 million shsMREOMereo BioPharma Group$2.76-0.7%$2.36$1.58▼$5.02$438.84M0.471.12 million shs1.24 million shsOPNTOpiant Pharmaceuticals$20.58$7.34▼$29.25$108.83M0.8477,920 shs562,700 shsSAGESage Therapeutics$6.70+1.5%$6.97$4.62▼$13.47$419.56M0.181.16 million shs647,192 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca-3.27%-7.50%+16.54%+2.78%-33.33%MREOMereo BioPharma Group-0.72%+0.73%+19.48%+5.34%-27.94%OPNTOpiant Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SAGESage Therapeutics+1.52%-2.19%+5.02%-13.21%-38.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca2.7334 of 5 stars3.50.00.00.03.82.51.3MREOMereo BioPharma Group1.6953 of 5 stars3.61.00.00.02.21.70.0OPNTOpiant PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASAGESage Therapeutics3.5629 of 5 stars3.01.00.04.01.41.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.57208.88% UpsideMREOMereo BioPharma Group 3.17Buy$7.67177.78% UpsideOPNTOpiant Pharmaceuticals 0.00N/AN/AN/ASAGESage Therapeutics 2.06Hold$8.8732.34% UpsideCurrent Analyst Ratings BreakdownLatest OPNT, ERAS, MREO, and SAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/25/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/9/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/27/2025MREOMereo BioPharma GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$7.003/26/2025ERASErascaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/26/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/21/2025ERASErascaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.003/21/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/18/2025MREOMereo BioPharma GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$2.10 per shareN/AMREOMereo BioPharma Group$1M438.84N/AN/A$0.36 per share7.67OPNTOpiant Pharmaceuticals$47.78M0.00N/A24.75$9.92 per share0.00SAGESage Therapeutics$47.40M8.85N/AN/A$7.56 per share0.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$125.04M-$0.62N/AN/AN/AN/A-42.26%-34.97%8/11/2025 (Estimated)MREOMereo BioPharma Group-$29.47M-$0.07N/AN/AN/AN/AN/AN/A8/12/2025 (Estimated)OPNTOpiant Pharmaceuticals$3.01M-$6.56N/AN/AN/A-147.90%-97.03%-59.66%N/ASAGESage Therapeutics-$400.67M-$5.80N/AN/AN/A-971.50%-68.18%-60.84%7/30/2025 (Estimated)Latest OPNT, ERAS, MREO, and SAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A4/29/2025Q1 2025SAGESage Therapeutics-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million3/26/2025Q4 2024MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.01$72.50 millionN/A3/20/2025Q4 2024ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/AOPNTOpiant PharmaceuticalsN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A11.0011.00MREOMereo BioPharma GroupN/A6.106.10OPNTOpiant Pharmaceuticals0.605.485.48SAGESage TherapeuticsN/A7.427.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%MREOMereo BioPharma Group62.83%OPNTOpiant Pharmaceuticals42.39%SAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipERASErasca14.40%MREOMereo BioPharma Group5.50%OPNTOpiant Pharmaceuticals25.15%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.29 million221.94 millionOptionableMREOMereo BioPharma Group40159.00 million148.74 millionOptionableOPNTOpiant Pharmaceuticals375.27 million3.87 millionNot OptionableSAGESage Therapeutics69062.62 million58.10 millionOptionableOPNT, ERAS, MREO, and SAGE HeadlinesRecent News About These CompaniesContrasting Sage Therapeutics (NASDAQ:SAGE) & Orgenesis (NASDAQ:ORGS)June 14 at 1:49 AM | americanbankingnews.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the InvestigationJune 12 at 10:00 AM | accessnewswire.comSage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Rating of "Hold" by AnalystsJune 11 at 2:44 AM | marketbeat.comBronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities InvestigationJune 10, 2025 | accessnewswire.comSquarepoint Ops LLC Has $126,000 Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)June 10, 2025 | marketbeat.comINVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. and Encourages Long-Term Investors to Contact the Firm - SAGEJune 9, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities InvestigationJune 8, 2025 | accessnewswire.comWall Street Zen Downgrades Sage Therapeutics (NASDAQ:SAGE) to SellJune 7, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to ConnectJune 5, 2025 | accessnewswire.comMajor Depressive Disorder Pipeline Appears Robust With 75+ Key Companies Actively Working in the Therapeutics Segment | DelveInsightJune 5, 2025 | theglobeandmail.comBank of America Corp DE Sells 355,277 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)June 4, 2025 | marketbeat.comAmeriprise Financial Inc. Trims Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)June 4, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach OutJune 3, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the InvestigationJune 1, 2025 | accessnewswire.comToronto Dominion Bank Makes New $742,000 Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)June 1, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Stock Rating Upgraded by Wall Street ZenJune 1, 2025 | marketbeat.comVoloridge Investment Management LLC Cuts Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 31, 2025 | marketbeat.comWhy Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?May 29, 2025 | zacks.comBronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities InvestigationMay 29, 2025 | accessnewswire.comMan Group plc Takes Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 28, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the InvestigationMay 27, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOPNT, ERAS, MREO, and SAGE Company DescriptionsErasca NASDAQ:ERAS$1.48 -0.05 (-3.27%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.48 +0.01 (+0.34%) As of 06/13/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Mereo BioPharma Group NASDAQ:MREO$2.76 -0.02 (-0.72%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.75 -0.01 (-0.33%) As of 06/13/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Opiant Pharmaceuticals NASDAQ:OPNTOpiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.Sage Therapeutics NASDAQ:SAGE$6.70 +0.10 (+1.52%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$6.72 +0.02 (+0.30%) As of 06/13/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
